These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 6697650)

  • 1. Sparteine oxidation by the human liver: absence of inhibition by mephenytoin.
    Jurima M; Inaba T; Kalow W
    Clin Pharmacol Ther; 1984 Mar; 35(3):426-8. PubMed ID: 6697650
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The molecular mechanisms of two common polymorphisms of drug oxidation--evidence for functional changes in cytochrome P-450 isozymes catalysing bufuralol and mephenytoin oxidation.
    Meyer UA; Gut J; Kronbach T; Skoda C; Meier UT; Catin T; Dayer P
    Xenobiotica; 1986 May; 16(5):449-64. PubMed ID: 2874666
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro metabolism of sparteine by human liver: competitive inhibition by debrisoquine.
    Otton SV; Inaba T; Mahon WA; Kalow W
    Can J Physiol Pharmacol; 1982 Jan; 60(1):102-5. PubMed ID: 7066751
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Polymorphic drug oxidation in humans.
    Eichelbaum M
    Fed Proc; 1984 May; 43(8):2298-302. PubMed ID: 6714436
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mephenytoin and sparteine oxidation: genetic polymorphisms in Denmark.
    Drøhse A; Bathum L; Brøsen K; Gram LF
    Br J Clin Pharmacol; 1989 May; 27(5):620-5. PubMed ID: 2757884
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro inhibition studies of two isozymes of human liver cytochrome P-450. Mephenytoin p-hydroxylase and sparteine monooxygenase.
    Inaba T; Jurima M; Mahon WA; Kalow W
    Drug Metab Dispos; 1985; 13(4):443-8. PubMed ID: 2863108
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Single-dose kinetics of clomipramine: relationship to the sparteine and S-mephenytoin oxidation polymorphisms.
    Nielsen KK; Brøsen K; Hansen MG; Gram LF
    Clin Pharmacol Ther; 1994 May; 55(5):518-27. PubMed ID: 8181196
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mephenytoin and sparteine pharmacogenetics in Canadian Caucasians.
    Inaba T; Jurima M; Nakano M; Kalow W
    Clin Pharmacol Ther; 1984 Nov; 36(5):670-6. PubMed ID: 6488688
    [TBL] [Abstract][Full Text] [Related]  

  • 9. S-mephenytoin, sparteine and debrisoquine oxidation: genetic polymorphisms in a Turkish population.
    Basci NE; Brosen K; Bozkurt A; Isimer A; Sayal A; Kayaalp SO
    Br J Clin Pharmacol; 1994 Nov; 38(5):463-5. PubMed ID: 7893589
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Extremely slow metabolism of amitriptyline but normal metabolism of imipramine and desipramine in an extensive metabolizer of sparteine, debrisoquine, and mephenytoin.
    Brøsen K; Gram LF; Kragh-Sørensen P
    Ther Drug Monit; 1991 Mar; 13(2):177-82. PubMed ID: 2053127
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interactions of bupranolol with the polymorphic debrisoquine/sparteine monooxygenase (CYP2D6).
    Pressacco J; Muller R; Kalow W
    Eur J Clin Pharmacol; 1993; 45(3):261-4. PubMed ID: 8276051
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro evidence against the oxidation of quinidine by the sparteine/debrisoquine monooxygenase of human liver.
    Otton SV; Brinn RU; Gram LF
    Drug Metab Dispos; 1988; 16(1):15-7. PubMed ID: 2894945
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of citalopram in relation to the sparteine and the mephenytoin oxidation polymorphisms.
    Sindrup SH; Brøsen K; Hansen MG; Aaes-Jørgensen T; Overø KF; Gram LF
    Ther Drug Monit; 1993 Feb; 15(1):11-7. PubMed ID: 8451774
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mephenytoin-type polymorphism of drug oxidation: purification and characterization of a human liver cytochrome P-450 isozyme catalyzing microsomal mephenytoin hydroxylation.
    Gut J; Meier UT; Catin T; Meyer UA
    Biochim Biophys Acta; 1986 Dec; 884(3):435-47. PubMed ID: 3096378
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of enzyme induction and inhibition on the oxidation of nifedipine, sparteine, mephenytoin and antipyrine in humans as assessed by a "cocktail" study design.
    Schellens JH; van der Wart JH; Brugman M; Breimer DD
    J Pharmacol Exp Ther; 1989 May; 249(2):638-45. PubMed ID: 2724144
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sparteine metabolism capacity in human liver: structural variants of human P450IID6 as assessed by immunochemistry.
    Tyndale RF; Gonzalez FJ; Hardwick JP; Kalow W; Inaba T
    Pharmacol Toxicol; 1990 Jul; 67(1):14-8. PubMed ID: 2395811
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro metabolism of the biguanide antimalarials in human liver microsomes: evidence for a role of the mephenytoin hydroxylase (P450 MP) enzyme.
    Helsby NA; Ward SA; Howells RE; Breckenridge AM
    Br J Clin Pharmacol; 1990 Aug; 30(2):287-91. PubMed ID: 2206791
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A human cytochrome P-450 characterized by inhibition studies as the sparteine-debrisoquine monooxygenase.
    Inaba T; Nakano M; Otton SV; Mahon WA; Kalow W
    Can J Physiol Pharmacol; 1984 Jul; 62(7):860-2. PubMed ID: 6498616
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Xenobiotic and endobiotic inhibitors of cytochrome P-450dbl function, the target of the debrisoquine/sparteine type polymorphism.
    Fonne-Pfister R; Meyer UA
    Biochem Pharmacol; 1988 Oct; 37(20):3829-35. PubMed ID: 2903741
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of sparteine oxidation in human liver by tricyclic antidepressants and other drugs.
    Otton SV; Inaba T; Kalow W
    Life Sci; 1983 Feb; 32(7):795-800. PubMed ID: 6827912
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.